BEAVERTON, Ore.--(BUSINESS WIRE)--Curadite, Inc. will compete for awards totaling up to $200,000 in the Epilepsy Foundation Shark Tank Finals, which take place in Aventura, FL on May 23, 2019 at the National Antiepileptic Drug and Device Trials. In its 8th year, the Shark Tank Competition identifies the “most innovative new ideas (and) support(s) the development and commercialization of an important new product, technology, or therapeutic concept to help people with epilepsy.” Winners are selected through a combination of judges (Sharks) and live voting by conference attendees. The Sharks include investors, industry luminaries, epilepsy advocates, physicians and scientists in the epilepsy community, and people with epilepsy.
Curadite will present their Medication Management Platform (MMP), which Curadite co-founders Dennis and Jody McNannay developed to address their daughter’s struggle with medication adherence for epilepsy. Non-adherence is a key factor in controlling epileptic seizures for the 65 million people worldwide who deal with epilepsy every day. Seizure control impacts clinical, social, and economic outcomes; the estimated healthcare cost of non-adherence in epilepsy patients ranges from $1,466 to $22,673 per patient/per year. According to the World Health Organization, 50 percent of Americans fail to take their medications as directed.
Curadite’s dedicated team of engineers have developed intelligent, unit-dose packaging, which utilizes wireless/cellular communicators to monitor and record per dose medication use. When medications are not taken, patients receive a gentle reminder. Curadite’s cloud management system gradually escalates communication to ensure the patient’s care team (parent, spouse, clinician, care buddy, etc.) is engaged to offer additional support, if and when needed. The MMP’s cloud-based platform utilizes a comprehensive, team-based, patient-centered approach to medication adherence. Clinicians can access real-time adherence data that provides objective feedback on patient adherence and treatment outcomes, providing an added layer of care for their patients.
Outcomes-based research suggests that higher rates of adherence in adolescents with epilepsy are possible with increased care team involvement during adolescent transition to medication self-management.
Curadite empowers patients, clinicians, caregivers and family members to work together to improve medication adherence with the support of our intelligently linked, proactive medication management platform.